{"brief_title": "Study Evaluating ReFacto in Hemophilia A", "brief_summary": "To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto\u00ae clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing laboratories (one in Europe and one in North America).", "condition": "Hemophilia A", "intervention_type": "Drug", "intervention_name": "BDDrFVII", "criteria": "Inclusion Criteria: - Patients who were or are enrolled in Study CTN 93-R833-0XX/C9741-28, and have been treated with ReFacto\u00ae during this study are eligible for participation. - The patient (or legal guardian) must be willing to give written informed consent before any study-related procedures are performed. - A blood sample will be collected from each patient for the purpose of this study and will be analyzed at one or both of the designated central laboratories. Exclusion Criteria: - Any condition which, in the investigator's opinion, places the patient at undue risk.", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00038909.xml"}